IRIS PHARMA FACT SHEET
A GLOBAL SERVICE PROVIDER OF PRECLINICAL AND CLINICAL RESEARCH IN OPHTHALMOLOGY

COMPANY OVERVIEW

Iris Pharma is a worldwide Contract Research Organization (CRO), dedicated to preclinical and clinical research in ophthalmology.

We take a global approach to the ophthalmology drug and device development process, and support clients ranging from small start-ups to large pharmaceutical companies in moving forward products that directly or indirectly affect eye health.

Since its founding in 1989, Iris Pharma has been based on the science of ophthalmology and has expanded its expertise in the field. Our unique, specialized knowledge ensures that our clients receive high-quality services delivered by well-informed and experienced staff who will guide their drugs or devices to market in the most efficient manner possible. We are proud to have partnered with clients to bring nearly 70 ocular drugs and medical devices to international market in the past 30 years.

SOLUTIONS FOR ANY OCULAR CHALLENGES

«I'd like to assess the possible therapeutic value of my lead compound»
«My product shows promise in treating ocular diseases. Help me to achieve high added value!»
«I need a full preclinical package or clinical trials for my ocular product»
«I need a step-by-step approach and "à la carte" studies»

QUALITY

At Iris Pharma, quality is a state of mind. Our quality assurance program is designed to ensure compliance with GLP, ICH-GCP and GCLP requirements, guidelines (FDA, OECD, etc.) and local regulatory laws and to maintain Iris Pharma’s standard of excellence in our work.

THERAPEUTIC EXPERTISE

Age-Related Macular Degeneration
Diabetic Retinopathy
Neurodegeneration
Retinal Ischemia
Glaucoma
Dry Eye Syndrome
Corneal Wound Healing
Ocular Infection
Ocular Inflammation
Conjunctivitis
Ocular Allergy
Ocular Pain
Ocular Surgery
Orphan Diseases
Cataract
Etc.

CERTIFICATIONS & ACCREDITATIONS

• Statement of compliance with GLP, GCLP and adherence to all trial-related requirements (ICH-GCP)
• Authorization No.2014-022762 to store for future use, to use, to import and to export radio-nuclides in sealed and unsealed sources
• Authorization No.D 06-065-9 for experiments on live animals
• French research tax credit accreditation (CIR)

KEY FACTS

Founded: 1989 by Pierre-Paul ELENA, PhD.
President: Yann QUENTRIC, M.Sc.
State of ownership: Private
Headquarters: Nice, France
Employees: 80
2017 Turnover: 8.6 M€
Clients: 350 international customers
FDA & EMA New Drug Approvals: 70
SERVICES FOR OCULAR DRUGS & MEDICAL DEVICES DEVELOPMENT

Benefit from the unique experience and background of an expert in ophthalmology

PRECLINICAL DEVELOPMENT SERVICES

We manage the complete animal ophthalmic development of drugs and devices using state of the art apparatus (Spectralis® HRA+OCT, tomography, confocal microscopy, electroretinography, laser flare meter, etc.).

- Early testing (proof of concept and pilot studies)
- In vivo pharmacology studies and animal efficacy models
- GLP regulatory studies: ocular pharmacokinetics, safety and tolerability
- Applied research (set up and validation of new and existing models and methods)

All studies are performed in-house by our technicians who have been trained to perform microsurgery of the eye and experimental procedure.

CLINICAL DEVELOPMENT SERVICES

We have been performing phase I to IV clinical trials and medical marketing surveys throughout Europe, North Africa, and North America. We provide our customers with the high-quality services necessary for evaluating new drugs and devices on patients, respecting regulatory authorities’ requirements.

- Regulatory support
- Study monitoring
- Site management
- Project management
- Data management and biostatistics
- Medical writing

- Investigational medicinal product (IMP) management*
- Pharmacovigilance*
- Bioanalytical testing services
- Central laboratory services

*Via our partners

3,000+ preclinical ocular studies completed
3,500 intravitreal injections/year
40+ animal efficacy models to mimic the conditions of the human eye
100% labs and animal husbandry dedicated to ophthalmology
110+ clinical studies and surveys conducted
40,000 patients involved in clinical studies and surveys
4,800 sites opened in 36 countries (Europe, North Africa and North America)

BIOANALYTICAL TESTING SERVICES

We develop, customize and validate assays of drug candidates and metabolites in a variety of ocular matrices to support preclinical, biopharmaceutical, and clinical pharmacology programs.

Analytical methodologies used include mass spectrometry, high-performance liquid chromatography coupled with different detectors, hematology analyzer, immunoassays (Luminex, ELISA, EIA and RIA), cell-based fluorescence assay (flow cytometry).

PRECLINICAL FORMULATION

We offer adequate non-GMP formulation of ocular drugs to be tested in preclinical studies, depending on the chemical properties of the compounds and the dosage form desired. We can also evaluate and improve the solubility of the compounds, with or without preservatives.

HISTOLOGY

We have been working for three decades on detailing and analyzing every structure of the eye, even going so far as to observe inflammatory cells in the vitreous body and aqueous humor.

CELLULAR AND MOLECULAR BIOLOGY ASSAYS

We work with our customers to identify and qualify predictive ocular biomarkers in many animal models - such as those involved in neovascularization. We also incorporate biomarkers quantification into clinical trials design such as HLA-DR (human leukocyte antigen) for ocular surface disease studies.

STRATEGIC CONSULTING SERVICES

We supply the necessary understanding and experience to guide new ophthalmic products through the development process. As a partner we help to direct preclinical and clinical drug development, to anticipate and plan for any issues which may arise, to design and manage drug and device development programs, or to provide strategic study design.

PARTNERING

- Institut de la Vision (a research center for eye diseases) to strengthen the bond between industry and academic research
- RxGen (a specialty preclinical CRO) to offer fully integrated “bench-to-bedside” ophthalmology research services
- Promedica International (a US-based CRO) to provide clinical research services in North America
- StreetLab (an innovative company for people with disabilities) to integrate quality of life in the clinical assessment of new products for use by the visually impaired
- Keen Eye (an image analysis specialist for the life sciences) to improve ophthalmology studies with artificial intelligence

Corporate Headquarters: Iris Pharma - Les Nertières - Allée Hector Pintus - 06610 La Gaude - France
Paris Office: Iris Pharma - Institut de la Vision - 13, rue Moreau - 75012 Paris - France
Ph: +33 4 93 59 49 59 - Fax: +33 4 93 59 49 50 - Email: info@iris-pharma.com - Web: www.iris-pharma.com

Last update Dec 2018